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INTRODUCTION 
One hundred years ago, the prognosis for a patient with ventricular 
fibrillation was fairly straightforward. Death ensued within a matter 
of five or six minutes. By the turn of the 20th century, scientists 
were beginning to understand the electrical and electrophysiologic 
nature of the heart. By the 1930s patients with cardiac conduction 
arrhythmias were being treated with both chemical and electrical means. 
With the advent of the transistor, permanently implantable stimulators 
became a reality in treating some cardiac arrhythmias. Currently, the 
pacemaker technology developed in the '60s and '70s is being extended to 
the treatment of ventricular fibrillation by means of implantable 
defibrillators (Mirowski et al., 1984; Thakor, 1984). The physical size 
of these devices is co~strained by the large capacitors and batteries 
needed for cardiac defibrillation. 
In an effort to reduce the size of the devices, one approach has 
been to investigate the use of the device in conj unction wi·th 
antiarrhythmic drugs. If a drug could be found that would decrease the 
energy needed to defibrillate the heart, the efficacy and reliability of 
the implantable defibrillator would improve. 
This thesis was undertaken to evaluate the effect of one such 
an tiarrhy thmic agent, amiodarone hydrochloride, on the defibrilla ti on 
threshold in dogs. Although anecdotal observations have been made in 
the clinical setting on the effect of amiodarone on other 
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electrophysiologic events in the heart, there has been no known 
q~antification of the effect of the drug on defibrillation thresholds in 
a controlled study. The question to be answered by this study is: Does 
amiodarone hydrochloride significantly reduce the defibrillation 
thresholds in dogs? 
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VENTRICULAR FIBRILLATION 
During a normal heartbeat, the myocardial cells depolarize in an 
organized, rhythmic fashion. Starting at the apex of the heart, a wave 
of depolarizing wave propagates upward to the base of the ventricles. 
This rh¥thmic motion reduces the intraventricular volume and forces the 
blood to move out of the chamber. 
Ventricular fibrillation is a condition characterized by the 
unsynchronized depolarization of the ventricular myocardial cells. With 
the loss of the rhythmic compression, the pumping action of the 
ventricles ceases, causing a loss of blood pressure. This is a life 
threatening situation, and if untreated, anoxia of the brain tissue and 
vital organs will result in death in a matter of minutes. 
Because of the suddenness of death, it is difficult to determine 
the exact sequence of physiologic events leading to specific cases of 
fibrillation (Harrison, 1972). However, it is well-established that 
fibrillation in general can be precipitated by myocardial infarction or 
disease, drug toxicity, metabolic abnormalities, hypothermia or electric 
shock (Geddes and Tacker, 1983). 
The mechanism of ventricular fibrillation has been explained by two 
popular theories, circus motion and multiple pacemaker sites (Tacker and 
Geddes, 1980). Both theories recognize the necessity for a critical 
mass of myocardium to maintain fibrillation. Without this critical 
mass, fibrillation cannot continue. That is the underlying reason why 
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small warm-blooded mammals such as cats, puppies, rabbits and rats will 
not normally sustain fibrillation (Geddes and Tacker, 1983). 
Before discussing the theories of fibrillation, it may be useful to 
review the normal cardiac conduction system. 
Normal Cardiac Conduction 
In a normal heart, the natural pacemaker site is located in the 
right atrium at the sino-atrial (SA) node. Rate determining P cells, or 
primitive cells, spontaneously depolarize. The depolarization impulse 
is rapidly conducted from the SA node to the atrio-ventricular (AV) node 
by three internodal pathways located in the atrium. The anterior, 
middle and posterior internodal pathways merge as they converge on the 
AV node, (James et al., 1982), As the impulse travels from the SA to AV 
node, the myocardial cells depolarize and the atrium contracts. A band 
of nonconductive tissue at the base of the ventricles prevents 
propagation of the atrial myocardial depolarization wave into the 
ventricular myocardium, The impulse conducted by the internodal 
pathways does continue into the ventricles after a slight delay at the 
AV node. The impulse travels down the Bundle of His located in the 
intraventricular septum, then branches out to the right and left 
ventricles. The rapid conduction of the pacing impulse is. then carried 
by the Purkinje fibers to the apex of the ventricles. K wave of 
depolarization spreads from the endocardium to the epicardium and 
progresses from the apex of the heart to the base. 
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The normal pacing impulse travels through this specialized 
conduction system much more rapidly than normal myocardial muscle 
tissue. Typically, the signal will be conducted through the Bundle of 
His at speeds of 2.5-5 meters/second, versus only 0.3-0.8 meters/second 
for myocardial tissue (Hamlin and Smith, 1977), with the conduction 
being more rapid at the apex than the base of the ventricles. 
The speed of conduction through these different ventricular tissues 
is important in establishing a coordinated wave of depolarization. The 
rhythmic contraction of the ventricles forces blood out of the chamber. 
When the wave of depolarization meets the nonconductive base of the 
ventricles, the muscle tissue stops contracting and repolarizes. The 
cycle normally repeats with the next P cell depolarization in the SA 
node. 
As the wave of depolarization -progresses from apex to base, the 
cells that depolarize are refractory for a short period of time before 
they repolarize. It is important to note that the propagation velocity 
of the depolarization wave and the refractory period of the tissue are 
not necessarily constant throughout the heart. 
Circus Motion 
Circus motion refers to the condition of continuous cardiac 
stimulation by a wave of depolarization that takes an abnormal, 
unending, circuitous route through the cardiac tissue. Using rings of 
cardiac tissue from turtle ventricles, Garrey, 1914 (cited in Geddes and 
< 
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Tacker, 1983) first described this mechanism for continuous stimulation 
of the ventricles. 
In a ring of normal turtle cardiac tissue, if one stimulates the 
bottom of the ring, a wave of depolarization will progress outward from 
the stimulation point. Two wavefronts will develop, one progressing in 
a clockwise direction around the ring, and the other going 
counter-clockwise. As the wavefronts travel around the ring, they are 
"followed" by a region of refractory cells, and further back, a region 
of repolarized cells. If the tissue possesses uniform conduc ti vi ty, the 
two waves will meet at a point diametrically opposite the stimulation 
point. As the wavefronts collide, each will encounter refractory cells 
from the other wavefront, and the propagation of both wavefronts will 
cease. If a second stimulation is initiated at the bot tom of the ring, 
it too will split into two wavefront and travel around the ring until 
either encountering the refractory region from the first stimulus, or 
colliding at the top of the ring. 
If, however, the propagation velocity of the wavefront through the 
tissue is not uniform, its possible for the wavefront collision to occur 
close to the original stimulation point, resulting in a region of 
refractory tissue very close to the point of stimulation. If this 
occurs, when a second stimulation is made, one wavefront may collide 
with the refractory region, leaving only the second wavefront to travel 
around the ring of tissue. If the length of the ring is long enough, 
the refractory period short enough, and the propagation velocity slow 
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enough, it is possible for the propagation wave to continue traveling 
its circuitous route uninterrupted. In Garrey's experiment, this 
"circus motion" continued for seven hours. 
Lewis, 1920 (cited in Tacker and Geddes, 1980) described a 
reentrant excitation mechanism (Lewis, 1920), which is similar to 
Garrey's circus motion theory. As a wave of depolarization progresses, 
it can only travel through tissue that is excitable. If it encounters 
inexci table tissue (a "block" according to Lewis), the wave will break 
in to daughter waves and go around the block. If the block is transient, 
such as with a region of tissue with a prolonged refractory period, it 
is possible for it to become "unblocked", or excitable, before the 
daughter waves have circumvented it. The "unblocked" tissue can be 
excited and change the direction of the depolarization wave, possibly 
causing a continuous wave of depolarization. 
The main difference between Garrey and Lewis's explanation of the 
mechanism for fibrillation is that the pathway for the reentrant 
mechanism can be different for each cycle of depolarization, whereas 
Garrey's model requires the same pathway each time. 
Multiple Pacemaker Sites 
The multiple pacemaker mechanism proposed by Scherf (Scherf and 
Teranova, 1949) states that fibrillation occurs when several 
asynchronous pacemaker sites are active simultaneously, causing the 
ventricles to contract continuously and without coordination. 
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Causes of Fibrillation 
Of the mechanisms of fibrillation mentioned, the circus motion and 
reentrant theories are considered "sustaining" mechanisms, whereas the 
I 
multiple pacemaker site theory has been referred to as a "precipitating" 
mechanism (Tacker and Geddes, 1980), There are several other causes of 
fibrillation besides the activation of multiple pacemaker sites, 
Myocardial inf arc ti on will cause a localized area of inexci table 
dead tissue, surrounded by a ring of poorly oxygenated tissue that is 
hyperexcitable and often autorhythmic (Tacker and Geddes, 1980), 
providing the precipitating mechanism for fibrillation. In addition, 
this surrounding ring of tissue's conductivity is nonuniform, permitting 
the sustaining mechanism of reentrant conduction. 
Low frequency electrical shock can precipitate fibrillation at 
voltages as low as 5 millivolts, if administered directly to the cardiac 
tissue during the vulnerable phase of the cardiac cycle (Wiggers and 
Wegria, 1940). Forty years previous to that, in 1899, Prevost and 
Ba ttelli reported on the effects of direct current, alternating current 
and capacitor-discharge current on the heart of mammals. They noted 
that low-voltage shocks produced ventricular fibrillation, but extremely 
high voltage (4800 volts) did not, 
Several pharmacological agents can induce fibrillat1on, such as 
large doses of epinepherine, digitalis or calcium salts. Each of these 
agents, in smaller doses, increases the contractility of the heart. In 
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an excessive dose, or in combination with several other drugs or 
anesthesias, these substances will initiate fibrillation. In addition, 
some environmental effects can induce fibrillation, such as hypothermia. 
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DEFIBRILLATION 
Several methods have been used successfully in the past to 
defibrillate the heart. Hooker, in 1930, described a chemical treatment 
for defibrillation. By injecting isotonic potassium chloride into the 
left ventricle, and forcing the solution through the coronary arteries, 
he was able to alter the extracellular potassium concentration to the 
extent that the myocardial cells spontaneously depolarized. After 
flushing the potassium chloride out of the coronary circulation, normal 
sinus rhythm was restored (Hooker, 1930). Later, he found that a 
subsequent injection of calcium chloride would increase the 
contractility of the heart, and improve the survivability of the heart. 
This method for defibrillation was used clinically, but had several 
drawbacks. First, 1 t necessitated the clamping of the aorta in order to 
force the potassium chloride into the coronary artery. This required 
emergency surgery to expose the aorta. Second, the concentrations of 
potassium chloride and calcium chloride could not be established for a 
large patient population. Each individual, depending on previous 
medication or metabolic state would require differing amounts of 
potassium chloride or calcium chloride. If an excess of potassium 
chloride were administered, the ventricles would be hypodynamic; too 
much calcium chloride could reinitiate fibrillation. By 1947, 
electrical defibrillation had replaced chemical defibrillation as the 
treatment of choice in the clinical setting. 
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In the early 1930s, Kouwenhoven and associates investigated the use 
of 60 Hertz current to defibrillate canine hearts (Geddes, 1984), 
although Prevost and Battelli had investigated electrical defibrillation 
in dogs as early as 1899, in Sweden. Beck et al. reported the first · 
successful human defibrillation in 1947. Using 110 volts A.C., they 
defibrillated a 14 year old boy. The device they used to defibrillate 
with consisted of two panel lights, a switch and two resistors. The 
length of the defibrillating pulse was determined by how fast one opened 
and closed the on-off switch (Geddes and H;,..lin, 1983). Currently, 
electrical defibrilla ti on is the method of choice for the treatment of 
ventricular fibrillation. 
Two main types of external defibrillators are currently employed, 
and are typically described by the shape of the defibrillating pulse 
that they produce. The capa~itor-discharge devices produce an 
exponentially decaying waveform, and the damped sinusoid defibrillators 
produce either underdamped or overdamped sine waves. 
\ 
The capacitor-discharge design stores electrical charge on large 
capacitors. When the capacitor ts discharged across the heart, the 
voltage and current exponentially drop from the peak stored value. The 
drop in the current waveform is called the "tilt" of the pulse, and can 
be small (approximating a square wave) or large (sometimes referred to 
as a trapezoidal wave). This energy delivery system can· result in large 
peak currents, which have been shown to impair myocardial contractility 
(Tacker et al., 1969; Geddes et al., 1970). 
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The second external defibrillator design incorporates an inductor 
in series with the output circuit. This design permits defibrillation 
wih less energy, voltage or current (Geddes et al., 1970). Although 
this appears to be a superior defibrillator design, for implantable 
defibrillator, the need for an inductor in the output circuit poses a 
serious design problem, since it is a bulky discrete component. Because 
of this, implantable defibrillators do not incorporate this design. 
Regardless of the design, these devices are effective in 
defibrillating the heart because they are able to maintain a threshold 
current density in a critical mass of ventricular tissue for a specified 
time (Niebauer et al., 1983a, 1984). This is es sen ti ally the criterion 
for defibrillation (Geddes and Tacker, 1983). 
Principles of Defibrillation 
Tacker and Geddes have literally written the book on electrical 
defibrillation (Tacker and Geddes, 1980). Through their study of the 
phenomenon, they have developed what they call the five "laws" of 
defibrillation. These laws address five important concepts: the 
strength-duration curve, the threshold distribution concept, the dose 
relationship, the average current hypothesis and the myocardial 
depression phenomenon (Geddes and Tacker, 1983). 
The strength-duration curve relates the length of the 
defibrillating pulse (the "duration") to the peak current of that pulse 
(the "strength"). In comparing animals of different body weigh ts and 
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species, the strength is generally normalized on the basis of heart 
wei:ght. The strength-duration curve for defibrillation is similar in 
shape to the strength-duration curves for muscle stimulation; that is, 
at short duration, a large amount of current is needed to defibrillate 
the heart. At longer durations, less current is required. The 
graphical relation is shown in Figure 1. 
Time 
Figure 1. Strength-duration curve 
Mathematically, this relation can be describ,ed by the following 
equation: 
I = b + k/d 
where I is the peak current, d is the duration of the pulse and k and b 
are constants dependent on heart size, electrode location and the shape 
of the waveform. This inverse Lapicque-type relationship exists only 
over a finite range of pulse durations. As the pulse duration lengthens 
over about 20 milliseconds, the current needed to defibrillate begins to 
increase. At pulse lengths greater than 30 msec., the current rises 
dramatically. One theory for this increase states that ·the cells that 
had depolarized prior to the beginning of the pulse come out of their 
refractory period and are refibrillated by the trailing edge of the 
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pulse (Schuder et al., 1966). 
The threshold distribution concepts states that the defibrillation 
threshold (DFT) measured in one animal with a given heart size may not 
be the same for another with the same heart size. Both intraspecies and 
interspecies differences in DFT exist. Geddes reported that in 
measuring the DFT in 49 dogs, using the same pulse duration and 
waveform, he found thresholds ranging from 11.4 to 42.5 mA./gram of 
heart tissue (Geddes and Tacker, 1983). The range of thresholds, 
however, was normally distributed. This normal distribution of 
thresholds permits a statistical analysis of DFT data. 
The dose relationship in defibrillation states that DFT is 
dependent on the size of the heart, bigger hearts requiring more energy 
to defibrillate than smaller hearts. This is true for both transches t 
defil)rillation and dfrect defibrillation. In studying thresholds for 
dogs, goats, horses, calves and sheep, Geddes characterized 
defibrillation energy versus heart weight with an exponential equation 
of the form: 
U = a (W)exp b 
where U is energy, W is heart weight and a and b are empirically derived 
constants (Geddes et al., 1974). Gutgesell et al. (1976) reported a 
linear, rather than exponential, energy/heart weight relationship in 
children under 50 Kg. He determined a 1 watt-sec/pound of body weight 
was generally needed for these patients. 
The dose relationship for defibrillation is not universally 
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accepted. Kerber noted that in patients with left ventricular 
hypertrophy resulting from aortic valve disease the proposed dose 
relation did not hold true (Kerber et al., 1980). 
The average current law of defibrillation states that for damped 
sine waves, square or trapezoidal waves at a given pulse duration, the 
average current for DFT is the same, regardless of waveform (Geddes and 
Tacker, 1983). This holds true for both direct and transchest 
defibrillation. 
I 
The myocardial depression phenomenon has been demonstrated to 
increase in severity with increasing shock strength, regardless of the 
waveform used for defibrillation (Niebauer et al., 1983b). Myocardial 
depression is characterized by a decrease in the peak systolic blood 
pressure following defibrillation. It is more severe when the 
defibrillation shock is shorter in duration (Niebauer et al., 1983a). 
It should be noted that the defibrillation shock itself is only one 
factor among many that contribute to myocardial depression. However, 
Neibauer has shown in controlled, isolated heart preparations that as 
current overdose increases, the percent decrease in pressure increases 
(Geddes and Tacker, 1983). 
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AMIODARONE 
Amiodarone hydrochloride is a class III antiarrhythmic drug with 
the structure of an iodinated benzofuran derivative (Gillis and Kates, 
1984). The structure of amiodarone appears below in Figure 2. 
Amiodarone was originally developed at Labaz Laboratories in Belgium in 
1962 as an antianginal coronary dilating agent (Singh, 1983), but it was 
soon shown to have other pharmacological properties, including 
prolonging myocardial action potentials, reducing the heart rate, and 
decreasing myocardial oxygen demand (Canada et al., 1983). It is 
currently used tn the treatment of ventricular and atrial arrhythmias. 
The drug has been studied since the late 1960s in Europe, and more 
recently in South America and the United States. Many of the effects of 
the drug have been reported, but the underlying mechanisms are still 
unclear. 
For example, the metabolism of the drug is not clearly 
characterized. Several potential metabolites have been proposed, but 
only desethyl amiodarone (see Figure 3) has been seen in the assays of 
blood from patients on long term medication (Latini et al., 1984). 
Figure 2. Amiodarone Figure 3. Desethyl amiodarone 
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The uptake of the drug is likewise unclear. The drug is absorbed 
following oral administration in an erratic and unpredictable fashion. 
The time to reach peak plasma concentrations measured in man have been 
reported to vary from 2 to 12 hours (Latini et al., 1984), and the 
apparent half-life of the drug has been reported anywhere from 15 to 45 
days (Canada et al., 1983). One reason for the erratic uptake that has 
been proposed is the low solubility of amiodarone in aqueous solutions, 
which may cause incomplete absorption across the in tes tin al mucosa 
(Gillis and Kates, 1984). Another proposed reason, based on studies of 
isolated perfused rat livers by Riva et al. (1982) that showed a high 
extraction ratio (.49), is that much of the amiodarone in the blood is 
removed on the first pass through the liver. This could account in part 
·for its low and variable bioavailability (Latini et al., 1984). 
The primary electrocardiographic effect of amiodarone that 
contributes to its utility as an antiarrhythmic is its ability to 
lengthen the action potential duration, or more specifically, the 
effective refractory period (ERP). In measuring the 50% and 90% 
repolarization times, S~ngh noted an increase related to the length of 
time on medication. After 1 week, repolarization time increased 11%, 
after 3 weeks it increased 23% and after 6 weeks on medication, the 90% 
repolariza ti on time had increased by 30% (Singh, 1983). · 
The increased ERP, if it occurs uniformly throughout the 
myocardium, is in itself an antiarrhythmic mechanism. With longer ERPs 
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it is more difficult for a reentrant type arrhythmia to become 
established, and multipacemaker sites have less opportunity to initiate 
an arrhythmia. 
This antiarrhythmic property, along with its long half-life, make 
amiodarone a desirable drug to be incorporated into system that combines 
an implantable defibrillator and an implantable drug infusion device for 
the treatment of recurrent fibrillation. To date, however, no one has 
made a quantitative, comparative study on the effect of amiodarone on 
defibrillation thresholds. For this reason, the following investigation 
was undertaken in an attempt to validate the use of amiodarone in this 
type of application. 
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METHODS AND MATERIALS 
The information on the use of animals in research and teaching was 
reviewed and approved by Dr. Joan Hopper of the Laboratory Animal 
Resources department. Two surgical procedures were performed on each 
animal in the study. The initial procedure was an aseptic determination 
of the transchest defibrillatton threshold of the animal. The follow-up 
procedure, six weeks later, was a nonsterile determination of both 
transchest and direct contact cardiac defibrillation threshold. In 
addition, an assay for blood and tissue levels of amiodarone was 
developed. 
Defibrillating Electrode and Stimulating Catheter Designs 
Prior to the surgery, a pair of external defibrillation electrodes 
were constructed using aluminum mesh and backed with .050 inch thick Dow 
silicone rubber reinforced with Dacron mesh. The circular electrodes 
measured 8 cm. in diameter, the same diameter as the chest electrodes 
supplied for the American Optical Model 10645 external defibrillator. 
The mesh was secured to the silicone rubber backing by applying Dow Type 
A medical adhesive to the perimeter of the mesh and curing at 200 
degrees Farenheit for 8 hours. An alligator clip was secured to each 
electrode to allow easy connection to the different type of 
defibrillators to be used in the procedure. A sketch of the electrodes 
appears in Figure 4. 
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Top Side 
Figure 4. External defibrillation electrodes 
-'. elect rod~ ~=:::;;;:=~co Grass stimulator  
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Figure 5. Stimulating catheter 
A bipolar, transvenous stimulating catheter was constructed from 
tubing and wire (see Figure 5). Two strands of teflon coated 30 gauge 
wire-wrap wire were pulled through a 30" length of .044 x • 065 polyvinyl 
tubing. Two 1/2" lengths of 18 gauge stainless steel hy"podermic needle 
stock were cut to form the proximal and distal electrodes. One strand 
of wire was soldered to the proximal end of the proximal electrode, and 
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the other wire was pulled through the bore of the proximal electrode. 
An overlap joint between the polyvinyl tubing and the proximal electrode 
was secured with Dupont Superglue. A 1/2" section of polyvinyl tubing 
· overlapped the distal end of the proximal electrode by 1/ 8" and was also 
glued. The second strand of wire was pulled through the distal 
electrode and soldered to the distal end of the electrode. The proximal 
end of the distal electrode was glued to the 1/2" section of tubing, and 
another l" piece of tubing was glued to the distal end of the distal 
electrode. This piece of tubing was back-filled with Dow Type A medical 
adhesive to prevent blood from flowing up the catheter. A slight 
"lazy-L" curve was formed in this most distal piece of tubing by gently 
heating over a Bunsen burner. The proximal ends of the wires were 
stripped and crimped ·to two 1/ 2" sections of 18 gauge hypodermic needle 
stock to provide an electical ""contact point for_ alligator clips. A 
second 36" length of .023 x .038" polyethylene tubing was glued along 
the length of the stimulating catheter to provide a pressure monitoring 
line to the right ventricle. The distal end extended to the section of 
tubing connecting the proximal and distal electrodes. A blunt 20 gauge 
needle was attached to the proximal end. 
Defibrillators 
Two defibrillators were used during the procedures: The first, an 
American Optical Model 10645 defibrillator, was a commercial unit that 
provides a damped sinusoidal defibrillation pulse. The output is 
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variable from 0 to 400 watt-seconds (i.e., joules). However, the output 
was difficult to accurately preset, and there was no direct way to 
monitor the output voltage and current pulse. This unit was used only 
as a backup device in the event that the primary defibrillator 
malfunctioned. 
Defibrillation thresholds were determined using a capacitor 
discharge defibrillator made by the Biomedical Engineering Center, 
Purdue University. The unit, called TED (Truncated Exponential 
Defibrillator), could be preset to any voltage between 0 and 1999 volts 
in one volt increments (see Figure 6). The tilt of the waveform could 
be varied, and was selected to be 63%. Provisions were made so the unit 
could be preset for a backup shock if the first shock was unsuccessful. 
Backup shocks were preset to roughly one and a half times the initial 
shock. Since oscilloscopes are unable to monitor the high voltages 
involved in defibrillation, the output pulse from the TED ran through a 
circuit that would scale the voltage waveform and also measure the 
scaled current wavef_orm. Two outputs on the back of the unit provided 
voltage and current waveforms with a voltage scaling factor of 400 
volts/volt, and a current scaling factor of 10 amps/volt. The voltage 
and current waveform outputs were connected to a Tektronic two channel 
differential oscilloscope, with one waveform inverted to get maximum 
resolution from the scope. 
Figure 6 . TED (truncated exponential defibrillator) 
N 
w 
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Transchest defibrillation thresholds were determined by using the 
TED with the chest electrodes. For direct defibrillation thresholds, 
the TED was connected to a pair of 4 cm. in diameter round, concave hand 
paddles. Surgical sponges soaked in normal saline were tied to the 
paddle faces to enhance the electrical contact and minimize the tissue 
damage caused by localized high current density contacts. 
Initial Procedure 
Prior to the initial procedure, the animals were given an oral 
antibacterial agent, Tribrissen (trimethoprim and sulphadiazine, 30 
mg./kg.; Burroughs Wellcome) for one day. The Tribrissen was 
administered to prevent infections arising from the surgery. Because of 
lack of personnel, it was necessary to break the sterile surgical ·field 
several times during the course of the threshold determination in order 
to adjust equipment. The antibiotics counteracted any inadvertent 
contamination of the surgical site. The animals were maintained on 
tribrissin (30 mg./kg./day) for up to five days after surgery, if the 
surgical site showed signs of infection (edema, redness). 
The dogs were prepared by being walked immediately before the 
surgery to empty the bowel and bladder. The dog's right forepaw was 
shaved, and an intravenous injection of 4-8 mg./lb. of Surita! (sodium 
thiamylal) was administered. An endotracheal tube was inserted, and the 
animal was maintained on Metofane (methoxyflurane) anesthesia. ·The tops 
of the right and left front paws and left hind paw were shaved to accept 
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EKG skin electrodes. The right and left side of the chest was shaved to 
accept the transchest defibrillation electrodes. The neck and inner 
left thigh were shaved, scrubbed with Betadine soap and alcohol and 
sprayed with Be tadine solution. 
The animal was then wheeled into the surgery room, and the EKG and 
transchest electrodes attached. Low resistance electrode paste 
(Liqui-Cor) was applied to both the defibrillation and EKG electrodes. 
The animal was placed in a slight left lateral recumbency position. The 
left transchest electrode was placed on apical beat location of the left 
side, as described by Geddes et al. (1977). This position was 
determined by either listening for the loudest heartbeat with a 
stethoscope, or, more commonly, observing the motion of the chest wall 
as the heart beat against it. The right transchest electrode was placed 
in the corresponding apical beat position. Its position had to be 
ascertained by listening, as no motion was apparent. The transchest 
electrodes were held in place with an elastic bandage (see Figure 7). 
The animal was then draped, and a femoral artery cut down made. A 
four-inch piece of polypropylene tubing.was inserted into the femoral 
artery, and was connected to a Statham PR-23Dc pressure transducer. The 
pressure waveform was displayed on a four channel Hewlett-Packard 
Sanborn 780-6A Viso scope monitor. 
Figure 7. Transchest electrodec held in place with elastic band£ge 
N 
°' 
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A right jugular vein cut down was then made and a stimulating 
catheter was inserted into the vein. The catheter's pressure tube was 
connected to a Statham PR-23 pressure transducer, and the resultant 
pressure waveform was displayed on the Sanborn monitor. The animal was 
given 100 units/lb •. of sodium heparin to prevent clot formation on and 
in the catheters. The tip of the jugular catheter was passed into the 
right ventricle. The position of the catheter tip was verified by 
viewing the distinctive pressure waveform on the monitor (see Figure 8). 
catheter in atrium catheter in ventricle 
Figure 8. Typical right ventricular pressure waveform 
The arterial and venous pressure and the EKG (lead II) were 
displayed on the Sanborn monitor, and recorded on a Hewlett-Packard 
Model 3960 4-channel instrumentation recorder. Fibrillation was induced 
with a Grass Model SD9 stimulator connected to the stimulating catheter 
with 18 gauge wires. The TED was connected to the chest electrodes by 
18 gauge wires, and the outputs from the TED were connec~ed to the 
oscilloscope. 
Once the stimulating catheter was in position, a 5 ml. blood sample 
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was taken for blood ·gas analysis on an Instrumentation Lab Model 513 
pH/Blood Gas Analyzer, and the threshold determination procedure 
commenced. A 2-5 second 5 volt peak to peak, 60 Hz. pulse from the 
stimulator was delivered to induce fibrillation. If the initial pulse 
was unsuccessful, a subsequent pulse of higher voltage was tried. If a 
5 second, 10 volt pulse would not induce fibrillation, the stimulating 
catheter was repositioned. 
Fibrillation was ascertained by both the drop in arterial pressure 
and the disorganized fibrillation pattern of the EKG waveform (see 
Figure 9). Fifteen to twenty seconds after successfully fibrillating 
the animal, a transchest defibrillating pulse was given. The fifteen 
second delay was needed to assure the animal was truly in fibrillation. 
Occasionally, an animal would spontaneously convert to a normal sinus 
rhythm immediately after the fibrillation pulse. 
The defibrillation pulse was delivered at the end of expiration. 
Successful defibrillation was determined by the rise in right 
ventricular pressure and reestablishment of a coordinated EKG waveform 
(see Figure 10). Defibrillation pulse leading and trailing edge 
currents and voltages were recorded, as well as the pulse width. The 
percent tilt of the waveform, leading edge impedance and pulse energy 
were calculated with a Texas Instruments TI-SSC calculator and recorded. 
EKG (lead II) 
60 Hz. stimulation 
- , .. ..... ..... ,~ 
Arterial Pulse 
Right Ventricular Pressure 
Figure 9. Fibrillation resulting from 60 Hz. stimulation 
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Figure IOa. Defibrillation and return of EKG and· blood pressure 
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Figure lOb. Direct defibrillation with hand-held paddles 
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If the animal was not successfully defibrillated, a higher voltage 
transchest defibrillation pulse was administered immediately. If this 
backup pulse was unsuccessful in defibrillating the dog, a third, much 
higher voltage, pulse was delivered. If necessary, additional 
transchest defibrillation pulses were given using an American Optical 
Model 10645 DC Defibrillation unit. These defibrillation pulses were 
delivered using the chest paddles supplied with the defibrillation unit. 
After defibrillating the animal, the EKG and pressure were closely 
monitored for arrhythmias or insufficient pressure. A ten minute rest 
was taken between each defibrillation episode to allow time for 
myocardial reperfusion. At the end of the rest period, most animals had 
recovered to the point where their arterial pressure and heart rate had 
returned to pre-fibrillation levels. In those animals that had not 
recovered to a near normal state, a longer rest period was permitted. 
After a successful defibrillation, the process was repeated at a 
new defibrillation voltage level. If the initial voltage setting had 
been successful, the next shock was set for a value 10% lower than the 
first. If the first shock had not worked, the voltage was set 10% 
higher. This determination of defibrillation values continued until the 
peak current of an unsuccessful defibrillation attempt was within 10% of 
the peak current of the last successful defibrillation. The latter was 
then considered the defibrillation threshold (DFT). 
After establishing OFT, the arterial pressure catheter was removed, 
the femoral artery tied off and the incision closed with 2-0 chromic gut 
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(Ethicon) and the skin closure made with 3-0 prolene. The stimulating 
catheter was removed, the jugular vein incision sutured with 6-0 
prolene, a subcutaneous closure was made with 2-0 chromic gut and the 
incision closed with 3-0 prolene. The EKG and chest electrodes were 
removed and the animal removed from anesthesia and watched until 
conscious, then returned to its cage. 
The animals were observed daily for any signs of infection and 
given proper medical attention if needed. For 6 weeks, eight animals 
were given daily oral doses of 200 mg. amiodarone hydrochloride, either 
as the injectable preparation (Cordarone, from Labaz Laboratories) or as 
a powder (Sanofi Recherches, Montpellier, France) in a gelatin tablet. 
The control animals received no medication. Weekly blood samples were 
taken from the animals on amiodarone. The plasma was frozen for future 
amiodarone concentration assay. 
Follow-up Procedure 
After six weeks on the study, each of the dog's transchest 
defibrillation threshold was determined in a follow-up procedure. In 
addition, direct heart defibrillation t~resholds were determined. 
Each animal was prepared for surgery in a manner similar to the 
initial protocol, with only a few alterations. Prior to anesthetizing 
with Surital, a 10 cc blood sample was taken from the dogs on amiodarone 
for analysis. For all animals, since the follow-up procedure was 
terminal, the surgical sites were not scrubbed, nor was an aseptic 
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method used during surgery. In addition to shaving the sides of the 
chest for defibrillation electrodes, the hair over the sternum was 
shaved. 
A pressure catheter wss inserted into the right femoral artery 
(since ·the left one had been tied off in the initial procedure). The 
stimulating catheter was inserted in the right jugular vein just caudal 
to the insertion site from the initial surgery. In animals that had 
totally occluded right jugulars, the left jugular was used. 
The transchest defibrillation thresholds were determined as 
described for the initial procedure. Following the determination of 
transchest threshold, a blood sample was taken, and the stimulating 
electrode was pulled out of the right ventricle. 
The s'ternum was then split open to expose the heart. The animal 
was kept on positive pressure ventilation by a Bird Mark 14 Positive 
phase ventilator. An approximately 3;' long longitudinal slit in the 
pericardial sac was made, permitting one to remove the heart from the 
sac while defibrillating and place it back within the sac during the 10 
minute res ts be tween shocks. 
Fibrillation was induced by touching the ventricular epicardium 
with a pair of stimulating electrodes connected to the Grass stimulator. 
Fibrillation was verified both visually and by a drop in arterial 
pressure. After a 15-20 second fibrillation period, the· hand-held 
defibrillation paddles were placed· on the right and left ventricular 
free walls, close to the base, and the heart was defibrillated (see 
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Figure lOa). To enhance the electrical contact between the heart and 
the defibrillation electrodes, the electrodes were covered with surgical 
sponges that had been soaked in normal saline. Voltage for the initial 
defibrillation setting was arbitrarily set for 400 vol ts. Subsequent 
voltage settings were 10% higher or lower, depending on the failure or 
success of the first shock. 
After establishing direct defibrillation threshold, a final blood" 
sample was withdrawn, the animal was terminated and the heart removed 
from the chest cavity. An examination was made for any obvious 
pulmonary anomalies, the presence of heart worms or any obvious 
myocardial abnormalities. The atria were trimmed away, and the 
ventricular mass was measured on a Torsion Balance Co. Model DLMS 
balance and recorded. The ventricles of the animals on amiodarone were 
frozen for future drug concen tr a ti on assay. 
Amiodarone Assays 
The concentration of amiodarone in the plasma and right ventricular 
free wall was determined with high performance liquid chromatography 
(HP.LC) using a technique similar to that described by P.lomp et al. 
(1983). 
The HP.LC equipment consisted of a Waters Associates Chromatography 
P.ump Model 6000A connected to a Spectra-Physics SP.8780 XR Sampler and a 
Waters uBondpack C-18 column (P./N 27324). The detector in the system 
was a Waters Lambda-Max Model 480 LC Spectrophotometer. The analog 
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signal from the detector was fed into a Nelson Analytical 760 Series 
Interface, and was digitally processed with Nelson Analytical 
Chromatography Software (Ver. 3.5) on an IBM XT Personal computer. Hard 
copies of the data were printed on an IBM Personal Computer Graphics 
Printer. 
The mobile phase for the assay consisted of 0.6% ammonium hydroxide 
(25%) in methanol, and was the same for both tissue and plasma assays. 
An internal standard solution of 18040 (provided by Sanofi Recherches) 
in acetonitrile (100 ug./ml.) was made, as well as a standard solution 
of amiodarone in acetonitrile (100 ug./ml.) and desethyl amiodarone in 
acetonitrile (100 ug./ml.). 
To assay the plasma, 1 ml. of plasma that had been taken from the 
amiodarone treated dogs just prior to termination was mixed with 0.2 ml. 
of the internal standard solution and 1. 8 ml. of ace toni trile, to make a 
3 ml. solution. The solution was vortexed for 5-10 seconds, and allowed 
to mix for 10 minutes on a rotary mixer. The samples were then 
centrifuged at maximum speed in a Beckman Model TJ-6 Centrifuge for 10 
minutes. The supernatant was transferred to a clean microfilter 
centrifuge tube (~ioanalytical Systems, West Lafayette, Indiana) 
containing a 0.45 micron filter. The samples were centrifuged at 
maximum speed in the TJ-6 for another 10 minutes, and the filtrate then 
pipetted into clean autosampler vials, capped and inserted into the 
Spectra-Physics autosampler. 
Calibration samples of control plasma were also run at the same 
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time. To prepare the six calibration samples, l ml. of plasma from a 
dog that had received no amiodarone was placed in each of six vials. 
Each vial then received 0.2 ml. of the internal standard, L8040.(100 
ug./ml.). Different amounts of amiodarone and desethyl amiodarone and 
acetonitrile were added to each vial to give calibration levels ranging 
from 0.33 to 3.0 ug. of amiodarone and desethyl amiodarone per 
milliliter of solution. The vials were then vortexed, centrifuged, and 
filtered as above. 
HPLC was run on each sample. The mobile phase had a flow rate of 
1.4 ml./min., and 20 microliter injections were made for each sample. 
The complete operating parameters for the data acquisition are listed in 
Appendix D. Data from the HPLC were recorded on a floppy disk. 
For plasma samp~es with low levels of amiodarone that could not be 
detected with this procedure, a method of concentrating the solutions 
was developed. Aliquots of the previously prepared 3 ml. solution were 
measured into vials and evaporated in a Savant Speed Vac Concentrator 
for 3 hours. The dried precipitate was reconstituted with 0.25 ml. of 
the mobile phase. This solution was placed in a clean microfilter tube 
(0.45 micron filter) and centrifuged for 5 minutes. The filtrate was 
pipetted into a clean autosampler tube. Aliquots from each of the four 
calibration solutions were likewise concentrated. 
To assay the tissue samples, approximately 0.2 gram~ of myocardial 
tissue was dissected from each right ventricular free wall near the apex 
of the heart from each dog. The tissue was minced, patted dry between 
37 
two pieces of clean filter paper and weighed on a Mettler analytical 
balance, an.d the mass recorded. The tissue was then placed in a glass 
tissue homogenizer with 1.0 ml. of 50% ethanol in water. After 
approximately 5 minutes of homogenization with a Con-Torque Tissue 
Grinder Assembly, the homogenate was poured into a vial, 0.2 ml. of 
in temal standard (L8040) solution added, and 1. 8 ml. of ace toni trile 
added. The solution was vortexed 15 seconds, mixed for 10 minutes, and 
centrifuged for 10 minutes. The supernatant was pipetted into a plastic 
microfilter tube, a 0.45 micron filter inserted, and the tube was 
centrifuged for 10 minutes. The filtrate was then pipetted into clean 
autosampler vials, capped and inserted into the Spectra-Physics 
autosampler. 
Calibration samples were also made for the tissue assay using 
tissue harvested from a dog that had received no amiodarone. Sufficient 
amiodarone and desethyl amiodarone were added to give four calibration 
levels ranging form 0 to 10.0 ug./ml. 
Sta tis tics 
The means and standard deviations of all the threshold data were 
calculated, as well as the body weight normalized and ventricular weight 
normalized thresholds. Comparisons between the control and amiodarone 
treated animals were made using a one-tailed Student's T-tes t. 
Significant changes were defined as p < .05. Slight differences were 
defined as p < .10. 
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All plots show population means with a bar indicating the standard 
deviation (standard error). Correlation coefficients are denoted by 
"r", and are the linear correlation coefficient of the plotted data. 
Equations shown on plots assume "x" to be the abscissa and "y" the 
ordinate. 
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CALCULATIONS 
Several threshold parameters were calculated from the voltage and 
current waveform data, including tilt, leading and trailing edge 
impedances, and pulse energy. A typical waveform is labelled below (see 
Figure 11). 
,_ 
0 
Figure 11. Typical defibrillation current waveform 
By definition, tilt is the decrease in current expressed as a 
fraction of the level of current at the beginning of the pulse, or: 
T = (Io - If) / Io 
where I
0 
is the leading edge current (amps), If is the trailing edge 
current (amps) and T is the tilt of the waveform. Tilt can be expressed 
as a percentage by multiplying the fractional value by 100. 
The leading and trailing edge impedances were calculated using 
Ohm's Law: 
and 
where Z0 , Zf are leading and trailing impedances (ohms), respectively; 
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V
0
, Vf are leading and trailing voltages (volts), respectively; and I
0
, 
If are leading and trailing currents (amps), respectively. Note that 
the impedance value is only resistive. This can be verified by noting 
the lack of phase shift between the current and voltage waveforms. 
Using the preceding definition of tilt, one can express the average 
current of a pulse by: 
I 
av = (T I 0 ) I ln (1/1-T) 
where I is the average current in the pulse. The derivation of this av 
equation appears in Appendix A. 
The energy of each pulse can be calculated from the current and 
voltage waveforms: 
where U is the energy in joules, tf is the duration of the pulse in 
seconds. The derivation of this equati~n appears in Appendix B. 
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RESULTS 
Initial Transchest Defibrillation Thresholds 
All the initial surgeries were successful, and transches t threshold 
values were obtained for each animal in the study. The follow-up 
surgery, however, did not proceed as smoothly, and several animals died 
during the open chest procedure. Dogs 5712, 5772, and 6031 died before 
the direct defibrillation thresholds could be determined. In each case, 
the heart had been successfully defibrillated, but either went into 
asystole, or it developed bradycardia with insufficient pressure to 
maintain the animal. In each case, the animal had a condition which may 
have contributed to the death of the animal. Dog 5712 had what appeared 
to be right ventricular hypertrophy. Dog 5772 had adult heart worms in 
the right ventricle, and d?_g 6031 had· a recently fractured sternum, as 
evidenced by its limping gait at the beginning of the study and 
subsequent visual inspection of the sternum during the open chest 
procedure. Two additional dogs were placed on the study to bring the 
direct defibrillation control population back to the originally planned 
eight. Subsequently, one of the replacement animals died during the 
direct defibrillation procedure. 
The data from the initial series of procedures were grouped 
together with the data from the replacement studies. Dog 5782 was used 
to develop the surgical technique for opening the chest, and the direct 
defibrillation thresholds from the animal were added to the control data 
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group. Because of this, the control and study group have different 
populations. 
For the purpose of comparison, the defibrillation data have been 
separated into six distinct groups: initial transchest thresholds 
(controls), initial transchest thresholds (amiodarone), follow-up 
transchest thresholds (controls), follow-up transchest thresholds 
(amiodarone), direct defibrillation thresholds (controls), and direct 
defibrillation thresholds (amiodarone). Data from each individual 
experiment, including total number of shocks (both primary and backup) 
needed to determine DFT, voltages and currents, are listed in Appendix 
C. Summaries of the group results and significant differences in 
population means are presented in this sec ti on. Significant differences 
in means were evaluated using a Student's one-tailed T-test at a 0.05 
level of significance. 
A summary of the initial defibrillation thresholds for the control 
animals is listed in Tables l, which compares the body weight no,rmalized 
threshold values of voltage, current and energy. As one would expect, 
since none of the amiodarone dogs had yet received any amiodarone, there 
is no significant difference between the control group and the 
amiodarone group for the initial transchest procedure. 
It is interesting, however, to note the rather broad spread of data 
for each parameter. One way to characterize this spread' is through the 
use of the' coefficient of variability (C. V.), which is defined as the 
standard deviation of a parameter divided by its mean. For example, the 
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C. V. for the body weight normalized energy was 42% and 33% for the 
control and amiodarone group, respectively. This represents a very 
broad, and imprecise measurement. The mean current was 25% and 20% for 
the control and amiodarone group, respectively. The body weight 
normalized mean current is the comparative parameter preferred by 
several investigators. However, the spread of data for the body weight 
normalized peak voltage was slightly less (C. V.'s = 22% and 16% for the 
controls and' amiodarone group, respectively). Perhaps the normalized 
peak current would be a more precise measure of defibrillation threshold 
than the mean current value. 
Table l. Initial transches t defibrillation, 
body weight normalized values 
(controls vs. amiodarone) 
Peak Mean Mean 
Voltage Voltage 
(V /Kg) (V /Kg) 
Peak 
Current 
(A/Kg) 
Current Energy 
(A/Kg) (J/Kg) 
Controls: 
N = 10 
Average = 47 
st. Dev. = 11 
Amiodarone: 
N = 8 
Average = 42 
st. Dev. = 7 
10 
32 
7 
8 
29 
5 
10 
.68 
.16 
8 
.63 
.13 
10 
.46 
.11 
8 
.43 
.09 
10 
1.11 
.46 
8 
.88 
.29 
Follow-up Transchest Defibrillation Thresholds 
The summary of the follow-up transchest defibrillation thresholds 
are reported in Tables 2A and 2B. Table 2A lists the body weight 
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normalized values, and Table 2B summarizes the heart weight normalized 
values. It would appear that the amiodarone treated animals required 
slightly (p < .10) lower normalized mean peak currents and lower body 
weight normalized energy, but the difference is not enough to be 
significant. 
Table 2A. Follow-up summary of transchest 
defibrillation thresholds, body weight 
normalized values (controls vs. amiodarone) 
Controls: 
N = 
Average = 
St. Dev. = 
Amiodarone: 
N = 
Average = 
St. Dev. = 
* 
Peak Mean 
Voltage Voltage 
(V/Kg) (V/Kg) 
10 
52 
14 
8 
46 
9 
10 
36 
10 
8 
31 
6 
.E. < .10. 
Peak 
Current 
(A/Kg) 
10 
.84 
.30 
8 
.64* 
.12 
Mean 
Current Energy 
(A/Kg) (J/Kg) 
10 
.57 
• 21 
8 
.44* 
.08 
10 
1.42 
.62 
8 
i.05* 
.30 
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Table 2B. Summary of transchest defibrillation thresholds, 
heart weight normalized values: follow-up controls 
vs. follow-up amiodarone 
---------------------------------------------------------------
Ventricle 
Mass 
(grams) 
Peak Mean 
Voltage Voltage 
(V/g) (V/g) 
Peak Mean 
Current Current Energy 
(A/lOOg) (A/lOOg) (J/lOOg) 
---------------------------------------------------------------
Controls: 
N = 
Average = 
St. Dev. = 
Amiodarone: 
N = 
Average = 
St. Dev. = 
* E. < .10. 
10 
126 
25 
8 
124 
11 
10 
7.37 
2.14 
8 
6.46 
1.11 
10 
5.04 
1.52 
8 
4.42 
.74 
10 
11.85 
4.95 
8 
9.12* 
1.84 
10 
8.07 
3.42 
8 
6.20* 
1.24 
10 
20.14 
9.89 
8 
14.91 
4.28 
If one compares the initial control group with the follow-up 
control group, it becomes apparent that the transchest thresholds for 
the control animals did not stay constant over the length of the six 
week study. The body weight normalized peak and mean current increased 
slightly (p < .10) from the initial procedure to the follow-up (see 
Figure 12). The amiodarone treated group did not show a rise in mean 
current. Indeed, be tween the initial and follow-up procedures, there 
were no noticeable (p > .10) changes in any of the normalized 
defibrillation parameters for the amiodarone treated animals. 
Oil 
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Peak Current 
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Mean Current 
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Follow-up 
Procedure 
Figure 12. Defibrillation threshold currents (initial vs. follow-up) 
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Although not in the original protocol, measurements of chest 
breadth and chest wall thickness for several animals were made. The 
chest breadth was measured across the chest at the end of expiration. 
The distance measured was the straight line span between the centers of 
the chest electrodes. The chest wall thickness was measured on the left 
side of the chest, at the location of the left chest electrode, A 
summary of the chest measurement appears in Table 3. Note that there 
was a significant difference in between the controls and treated group 
in the chest breadth measurement, The amiodarone dogs tended to have 
narrower chest breadth measurements. 
Table 3. Summary of chest parameters: 
control vs. amiodarone 
Control: 
N = 
Average = 
st. Dev. = 
Amiodarone: 
N = 
Average = 
St, Dev. = 
* £. < .05. 
Chest 
Breadth 
(cm) 
7 
12 
l 
8 
io* 
l 
Chest Wall 
Thickness 
(cm) 
7 
l 
0 
6 
l 
0 
The chest measurements were taken because it was felt that the 
diameter of the chest and the chest wall thickness may be related to the 
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transchest threshold. It was presumed that the wider chests and chests 
with thicker walls would present a greater impedance to the 
defibrillation pulse. In retrospect, this measurement was unnece.ssary, 
since the impedance of all the tissue between the transchest electrodes 
could be determined from the voltage and current waveforms. From the 
follow-up threshold data in Appendix C and chest data in Table 3, we 
observe that the amiodarone dogs had significantly narrower chests (p < 
.05), but slightly higher impedances (p < .10). If one plots the chest 
diameter against the measured chest impedance, it becomes obvious that 
there is no linear correlation be tween chest bread th or chest wall 
thickness and tissue impedance (see Figure 13). 
Direct Defibrillation Thresholds 
The summary results of the direct defibrillation threshold 
determination appear in Tables 4A and 4B. Because dogs 5712, 5772 and 
6031 died during the direct defibrillation procedure, electrical data 
from these animals are not included in the tables. 
No significant differences were noted for the body weight 
normalized direct defibrillation thresholds, although the mean and peak 
currents were slightly (p < .10) lower for the amiodarone treated 
animals. 
In Table 4B, the control and amiodarone group are compared on a 
heart weight normalized basis. Again, there is no significant 
difference, although the mean current for the amiodarone treated animals 
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Table 4A. Summary of direct defibrillation 
thresholds normalized on a body weight 
basis: control vs. amiodarone 
Control: 
N = 
Average = 
St. Dev. = 
Amiodarone: 
N = 
Average = 
St. Dev. = 
* 
Peak Mean 
Voltage Voltage 
(V/Kg) (V/Kg) 
8 
19 
5 
8 
17 
4 
8 
13 
3 
8 
11 
3 
£. < .10. 
Peak Mean 
Current Current Energy 
(Amp/Kg) (Amp/Kg) (J/Kg) 
8 
• 25 
.05 
8 
• 21 * 
.03 
8 
.16 
.03 
8 
.14* 
.02 
8 
.18 
.07 
8 
.14 
.06 
Table 4B. Summary of direct defibrillation thresholds 
normalized on a heart weight basis: 
controls vs. amiodarone 
Control: 
N = 
Average = 
St. Dev. = 
Amiodarone: 
N = 
Average = 
St. Dev. = 
* 
Peak Milan 
Voltage Voltage 
(V/g) (V/g) 
7 
2.70 
.67 
8 
2.37 
.59 
7 
1. 79 
.46 
8 
1.59 
.41 
£. < .10. 
Peak Mean 
Current Current Energy 
(A/lOOg) (A/lOOg) (J/lOOg) 
7 
3.44 
.62 
8 
2.96 
.59 
7 
2.30 
.44 
8 
1.97* 
• 39 
7 
2.58 
.87 
8 
2.04 
.88 
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Concentrations of amiodarone in serum and cardiac tissue are listed 
in Table 5. Each animal in the amiodarone treated group had detectable 
serum and tissue concentrations of the drug, although the range of 
concentrations was rather broad (% C. V. = 56 for serum, 58 for tissue). 
Table 5. Amiodarone concentration 
in plasma and tissue 
Dog 
Number 
5773 
5797 
5830 
5834 
5835 
5878 
5953 
5954 
N 
Average 
St. Dev. 
% c. v. 
Plasma 
Concentration 
{ug/ml) 
= 
= 
= 
= 
.69 
.56 
.14 
• 26 
.17 
.48 
.27 
.26 
8 
.34 
.19 
56 
Tissue 
Concentration 
( ug/ml) 
4.4 
10.0 
2.8 
2.6 
5.5 
11.4 
5.6 
5.9 
8 
6.0 
3.5 
58 
To determine if a linear correlation exists between amiodarone 
concentration and defibrillation threshold, the data were plotted in 
Figure 14. The linear correlation coefficient for the data is 0.58, 
indicating a low correlation between amiodarone concentration and 
defibrillation threshold. 
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Blood Gasses 
The po2, pC02 , pH and base excess for each initial transchest 
procedure are listed in Table 10 (controls) and Table 11 (amiodarone). 
The blood gas data for the follow-up procedure are listed in Table 12 
(controls) and Table 13 (amiodarone). 
Blood samples for dog 5733 (initial surgery) and dog 5834 
(follow-up surgery) were inadvertently not taken. 
Because the animals were on Metofane mixed with 100% oxygen, the 
p02 levels were often abnormally high. In addition, the animals tended 
to acidotic and had elevated pC02 values. 
In Tables 8 and 9 one will note a substantial decrease in p02 
between the second and third blood sample. The second blood sample was 
taken just prior to opening the chest, and the third sample was taken 
just a before terminating the animal. During the interim, the animal 
was ventilated with a mechanical respirator. In several animals, the 
artificial ventilation pressure was too low to fully inflate the dogs 
lungs. This resulted in a substantial decrease in po2• 
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Table 6. Blood gasses for initial controls 
-----------------------------------------------------------
Dog Sample a pH pC02 p02 Base Excess Date -----------------------------------------------------------
5712 1 7.29 60.5 356.6 0.4 7/3 
2 7.37 58.2 414. 7 5.6 
3 7.35 60.0 418.5 5.3 
5762 1 7.50 47.9 130.5 11.8 7/10 
5774 1 7.26 58.9 359.9 -2. 7 7/26 
2 7. 28 53.9 373.4 -2.5 
5771 1 7.38 43.2 422.1 -0.1 7/29 
2 7.39 42.9 384.2 0.9 
3 7.42 40.0 367.8 1.2 
5772 1 7.30 51. 7 354.6 -2.3 7/31 
2 7.35 51.5 154.0 1.2 
5780 1 7.25 55 485.8 -3.4 8/5 
2 7.26 49.4 462.4 -4.7 
6031 1 7.28 59.1 367.1 -0.9 11/7 
2 7.25 62.8 293.3 -1.6 
6041 1 7.23 61.8 310.7 -3.9 11/12 
2 7.20 70.2 302.4 -3.4 
5802 1 7.27 63.1 318.7 o.o 9/17 
2 7.17 85.2 333.2 -0.9 
3 - clotted -
-----------------------------------------------------------
a 
1 taken at start of Sample - surgery 
Sample 2 - taken just prior to transchest procedure 
Sample 3 - taken just after transchest OFT. 
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Table 7. Blood gasses for initial amiodarone dogs 
-----------------------------------------------------------
Dog Sample a pH pC0
2 
po
2 
Base Exces·s Date 
-----------------------------------------------------------
5802 
5830 
5797 
5834 
5835 
5773 
5954 
5953 
5878 
a 
1 
2 
3 
1 
2 
3 
1 
2 
3 
1 
2 
3 
1 
2 
3 
1 
2 
3 
1 
2 
1 
2 
1 
2 
7.28 
7.30 
7. 29 
7.33 
7.31 
7.34 
7.29 
7.31 
7.33 
7.27 
7.19 
7.20 
7.34 
7.28 
7.28 
7.27 
7.24 
7.30 
7.19 
7.12 
7.35 
7.32 
7.27 
7.29 
57.3 
54.4 
60.l 
42.9 
50.0 
44.3 
50 
50 
48 
48.9 
62.4 
62.5 
45 
55 
55 
62.2 
67.3 
59.0 
80.3 
101.0 
51.9 
54.2 
56.3 
54.5 
488.7 
494.8 
526.4 
253.3 
321.4 
300.8 
370 
424 
424 
372.4 
340.0 
319.8 
484 
504 
527 
363.0 
326.7 
304.l 
439.l 
445.7 
461 
439.6 
374.7 
384.4 
Sample l - taken at start of surgery 
0.1 
o.o 
1.6 
-3.0 
-0.9 
-1.8 
-2.l 
-0.8 
-0.9 
-4.3 
-4.3 
-3.4 
-1.6 
-1.0 
-0.8 
-0.5 
-1.4 
0.4 
-0.3 
-0.9 
1.5 
0.4 
-2.9 
-1. 6 
8/2 
8/9 
8/14 
8/16 
8/21 
8/27 
10/29 
10/31 
11/4 
Sample 2 - taken just prior to transchest procedure 
Sample 3 - taken just after transchest DFT. 
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Table 8. Blood gasses for follow-up control dogs 
-----------------------------------------------------------
Dog Samplea pH pC02 po2 Base Excess Date -----------------------------------------------------------
5712 
5733 
5762 
5772 
5774 
5771 
5782 
5780 
6031 
6041 
a 
b 
1 
2 
1 
2 
3 
1 
2 
3 
1 
2 
1 
2 
1 
2 
3 
1 
2 
3 
1 
2 
1 
2 
3 
7.30 
7.19 
7.25 
7.24 
48.2 
60.9 
53.2 
52.8 
317.3 
374.9 
364.3 
402.3 
-- clotted sample --
7.34 
7.46 
7.44 
7.30 
7.26 
7.48 
7.36 
7.28 
7. 29 
7.40 
7.31 
7.44 
7.26 
7.23 
7.23 
7.28 
7.18 
7.31 
7.29 
7.31 
46.3 
32.6 
32.1 
56.5 
62.9 
97.4 
48.8 
51. 7 
54.5 
38.0 
468.9 
216.8 
84.4 
296.2 
275.9 
49.3 
52.2 
218.9 
289.4 
118.3 
43 342 
-- no sample taken 
32 524 
72.1 
86.9 
93.6 
52.9 
64.0 
48.4 
52.9 
48.7 
192. 8 
339.5 
19. 9 
407.8 
378.0 
285.1 
311.6 
70.4 
Sample 1 - taken at start of surgery 
-2.4 
-4.9 
-4.0 
-4.9 
-0.7 
-0.2 
-2.0 
-2.5 
-0.8 
39.5 
1.5 
-3.5 
-1.6 
-2. 9 
-4.4 
-2.1 
2.1 
4.6 
9.1 
-3.0 
-6.3 
-2.6 
2.7 
-2.1 
8/12 
8/19 
8/22 
9/5 
9/10 
9/12 
8/7 
10/3 
11/21 
11/26 
Sample 2 - taken just prior to transchest procedure 
Sample 3 - taken just after direct DFT. 
Venous blood sample. 
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Table 9. Blood gasses for follow-up amiodarone dogs 
Dog Samplea pH pC02 po2 Base Excess Date -----------------------------------------------------------
5830 
5797 
5835 
5773 
5954 
5953 
5878 
1 
2 
3 
1 
2 
3 
l 
2 
1 
2 
3 
1 
2 
3 
1 
2 
3 
1 
2 
3 
7.31 
7.28 
7.28 
7.27 
7.35 
7.40 
7.26 
7.20 
7.28 
7.26 
7.10 
7.25 
52.5 
53.4 
55.5 
62.4 
45.2 
41.7 
60.7 
71.0 
48.3 
49.3 
79.5 
45.0 
278.5 
263.9 
89.9 
364.8 
365.4 
373.8 
436.6 
416.6 
250.5 
238.1 
41.9 
392.1 
--- no sample taken ---
7 .18 59.7 86.8 
7.38 
7.32 
7.25 
7. 19 
7.25 
7.08 
40.9 
42.5 
48.8 
66.9 
56.6 
78.7 
465 
468 
141.3 
349.5 
375.5 
47 .8 
-1.3 9/19 
-2.8 
-3.6 
-0.7 9/24 
-1.1 
0.9 
-2.0 10/1 
-2. 6 
-4.8 10/8 
-5.5 
-6.5 
-7.7 12/12 
-4.3 
-1.1 12/18 
-4.5 
-6.5 
-5.2 12/19 
-4.0 
-8.3 
-----------------------------------------------------------
a 
Sample 1 - taken at start of surgery 
Sample 2 - taken just prior to transches t procedure 
Sample 3 - taken just after direct DFT. 
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DISCUSSION AND CONCLUSION 
The results indicate that amiodarone had no significant effect on 
either transchest or direct defibrillation thresholds. Several concerns 
must be addressed before this conclusion can be made with confidence. 
First, why did the control group's transchest threshold increase from 
the initial procedure to. the follow-up procedure? Second, did the 
amiodarone treated animals have concentrations of amiodarone high enough 
to have caused an electrophysiologic effect? And third, were there any 
metabolic conditions that could have masked the effect of amiodarone? 
Temporal Stability of Defibrillation Thresholds 
While the control group showed a slight increase in mean current 
from the initial to the follow-'up transches t procedure, it was not 
s ta tis tic ally significant. 
One would expect the control transchest ·thresholds to not change, 
or to decrease slightly over time, based on previous investigations. 
Kerber et al. (1983b), demonstrated that DFT remains constant over 
several hours in a series of transchest dog defibrillation experiments. 
Recent work by Ruffy et al. (1986) indicated thresholds in a 7 dog, 5 
day study decreased on the second day of the study, then remained 
constant for the remaining 3 days. They hypothesized th.at the 
defibrillations on the first day of the study caused enhanced myocardial 
sympathetic activity, which resulted in lowered DFT in subsequent 
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trials. While the Ruffy study did show a decrease in DFT, there is no 
known data on the long term stability of defibrillation thresholds in 
dogs (Ruffy et al., 1986), 
Therapeutic Levels of Amiodarone 
Several investigators have studied the effects of amiodarone 
without measuring the blood or tissue concentrations. In long term 
medication, it had been assumed that the patient would be at therapeutic 
levels if one prescribed the proper dose. However, this is a dubious 
assumption to make, since amiodarone has been shown to have variable 
uptake and metabolism rates. Early investigators compensated for this 
variable up take by heavily me di ca ting patients with a "loading" dose of 
1200 mg./day for adult humans for a week, then cutting the medication 
back to a "maintenance" dose of 200-400 mg. /day. Having done this, it 
was assumed any electrophysiologic phenomenon noted would be due to the 
effects of the amiodarone, without actually assaying for the drug. 
As HPLC techniques for detecting amiodarone developed, researchers 
began quantifying their results, and began specifying therapeutic and 
toxic ranges for amiodarone. 
In human studies, the therapeutic range of serum concentration has 
been reported as 1.0 to 3.5 ug./ml. in humans by Zipes et al. (1984), 
although the same group found levels as low as 0.6 ug./ml. in their 
patients. In another study cited by Gilles and Kates (1984), the 
suggested therapeutic serum concentration range was 0.5 to 3.0 ug., 
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although the range of efficacy of amiodarone in controlling arrhythmias 
was 0.1 to 11.9 ug./ml. in a study of 18 human patients. Latini et al. 
(1984) found a therapeutic mean of .67 ug./ml. (s. d. = .31, N = 24). 
The average serum concentrations found in this current study was 
.34 ug./ml. (s. d. = .19), which is significantly lower (p = .005) than 
the levels described by Latini. From examination of the serum levels 
alone, it would appear that the amiodarone treated dogs were not at 
therapeutic levels. 
However, in evaluating the concentrations of amiodarone, one must 
differentiate between serum and tissue levels of the drug. Most 
commonly, amiodarone levels are determined from serum, although it is 
thought that the myocardial tissue level of amiodarone is more 
reflective of its therapeutic characteristics (Connolly et al., 1984). 
Data on myocardial concentrations of amiodarone are difficult to 
find, since the tissues biopsies required for living patients are a 
rather traumatic, and not normally performed in a clinical setting. 
Magioni et al. (cited by Latini et al. 1984) did report on the 
concentrations of amiodarone in heart ti~sue that had been taken during 
an autopsy. He found a cardiac tissue concentration of 5 ug./ml. in a 
patient that had been on amiodarone for a long term. 
The average tissue concentration found in this study was 6.0 
ug./ml. (s. d. = 3.5). This would tend to support the idea that the 
amiodarone concentration in the animals was at a therapeutic level at 
the time of the follow-up surgery. 
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In the results, it was noted that there is a low correlation 
between the concentration of amiodarone in the tissues and the 
defibrillation thresholds. A low correlation between amiodarone 
concentration and other electrophysiologic effects has been noted by 
other investigators. Connolly et al. (1984) studied the effect of bolus 
injections of amiodarone on EKG timing intervals in dogs. He found a 
wide variation in animal response to the amiodarone, which could not be 
correlated to the measured myocardial or plasma tissue levels of 
amiodarone. 
Based on the facts that the dosing used in this experiment is 
comparable to that used by other investigators, and the tissue 
concentrations measured are similar to those few reported by others, it 
is concluded that there is a high probability that the amiodarone 
treated dogs were at ~ therapeutic level. 
Influence of Blood Gasses on Defibrillation Thresholds 
Several metabolic conditions can influence defibrillation 
thresholds. Until recently, it was thought that metabolic acidosis 
would increase defibrillation thresholds (Kerber et al., 1983a). In a 
later study, however, Kerber et al. (1983b) found that neither metabolic 
nor respiratory acidosis had an effect on canine DFT. Therefore, 
although all the animals is this current study showed signs of 
compensated respiratory acidosis, the acid/base balance should not have 
had an effect on defibrillation. 
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The one metabolic abnormality that Kerber found that did influence 
DFT was hypoxia, which caused a significant (p < .01) decrease in DFT. 
The· finding of a hypoxic effect was supported by Lake et al. ( 1984) in a 
human prospective study. None of the animals in this study were 
hypoxic, but most were hyperoxic. There is no known effect of high 
levels of po2 on defibrillation thresholds, although research in the 
area of hyperbaric oxygen toxicity has indicated two major effects on 
the cardiovascular system from hyperoxia in man. Paradoxically, both 
bradycardia and increased heart rate have been attributed to hyperoxia. 
Schaefer (1982) claims bradycardia is of vagal origin, and increased 
pulse rate and blood pressure can be due to increased sympathetic 
activity. Schaefer also noted that potassium ions accumulate in the 
extracellular fluid in rats that had been exposed to 100% oxygen at four 
times the normal atmospheric pressure. This increase had been 
attributed to the inhibition of the sodium-potassium ATPase by the high 
level of oxidants in the blood. 
If an increase in extracellular potassium occurs at normal 
anesthesia pressures, it could have an effect on defibrillation 
thresholds. Babbs et al. (1980) demonstrated that transchest 
defibrillation thresholds would fall during potassium intoxication. If, 
by breathing 100% oxygen, the animals in this study had increased 
potassium levels it is possible the defibrillation thresholds were low, 
and the effect of the amiodarone could have been masked by the altered 
potassium levels. However, there was no evidence found in the 
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literature that would indicate that potassium levels are altered by 
breathing 100% oxygen at normal ventilation pressures. Perhaps in 
future studies, the potassium levels of plasma could be monitored to 
verify they remain normal during the procedure. 
Conclusion 
In studying defibrillation thresholds, it is important to realize 
the limitations of the investigation. Several environmental conditions 
can have an effect on the measurement of transchest DFT. The location 
and contract pressure of the transchest paddles, the conductivity of the 
electrode paste, body weight, heart weight and cardiac temperature are 
parameters affecting threshold. It should be noted that the importance 
of these parameters 1.8 not universally accepted by all investigators. 
For example, the heart weight parameter that Geddes et al. claim is 
important for predicting defibrillation thresholds, is disputed by Lake 
et al. (1984) who found this to be important only at low level ( < 1 
joule) direct defibrillation. 
In planning the protocol for this thesis, an attempt was made to 
use established techniques for evaluating defibrillation thresholds. 
The surgical approach, placement of transchest and direct defibrillation 
paddles, the calculation of threshold values, the amiodarone dosing 
levels and the assay technique for evaluating tissue and plasma 
concentrations of the drug were modeled after established techniques 
used by major investigators. As a result, I am confident in concluding 
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that the results of this study show amiodarone hydrochloride may have 
slightly depressed thresholds, there is no statistically significant 
effect on lowering either transchest or direct defibrillation 
thresholds. 
Babbs, c. F. 1981. 
an tiarrhy thmic 
9:362-363. 
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APPENDIX A: CALCULATION OF AVERAGE CURRENT 
The current from a charged capacitor flowing through a resistive 
element can be described mathematically as 
i(t) =I exp(-t/T) 
0 
(1) 
where i(t) is the time dependent current, I is the initial current, t 
0 
is the time and T is the time constant (RC time constant) of the 
circuit. The average current during a pulse can be described as i av 
Iav = (l/~t) f i dt (2) 
Substituting equation (1) into (2), and evaluating the integral from t = 
0 to t = tf' where tf is the end of the defibrillation pulse, we find 
Iav = (-T/tf) (I
0 
exp (- tf/T) - I
0 
) 
Since i(tf) = I
0 
exp (-tf/T) =If' then 
Iav = (-T/tf) (If -Io) 
(3) 
( 4) 
Now, note that If =I
0 
exp (-tf/T). Taking the natural log of both sides 
and rearranging, 
(-T/tf) = -1/(ln I
0 
- lnif) 
Substituting into equation (4) and rearranging, 
The tilt (T) of a current pulse has been defined as 
Rearranging, 
1 I (l - T) = I
0 
I If 
(5) 
(6) 
By taking the natural log of both sides, we can substitute into equation 
76 
(6) to get 
and since I T = I - If' then 
0 0 
I =TI / ln (1/(1-T)) 
av o 
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APPENDIX B: CALCULATION OF PULSE ENERGY 
For a capacitive discharge into a resistive load, current and 
voltage vary as follows: 
i(t) = 1
0 
exp (-t/T) and v(t) = V
0 
exp (-t/T) 
where i(t), v(t) are the time dependent current and voltage, 
respectively; 1
0 
and V
0 
are the initial current and voltage, 
respectively; and T is the RC circuit time constant. The energy within 
a single pulse can be calculated by the integral 
u = f v i dt 
evaluated from t = 0 (start of the pulse) to t = tf (end of the pulse). 
Or, 
Evaluating the integral, 
From Append_ix A, we know 
T = tf I ln (l I 1-T) 
so equation (1) becomes 
U = (l0 V0 tf (1 - exp (-2tf/ T)) I 2 ln (1/1-T) 
Since the tilt '(T) of the defibrilla tion pulse is defined as 
Then, 
2T - T2 = (I 2 -I 2) I I 2 
0 f 0 
(1) 
( 2) 
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and since 
Then, 
= (I 2 -I 2 exp (-2tf/T)) / I 2 
0 0 0 
or, 
(2T - T2) = l - exp (-2t /T) . f 
Substituting into equation (2), we conclude 
U = (1
0 
V
0 
tf (2T - T2)) / (2 ln (1/1-T)) 
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APPENDIX C: THRESHOLD DATA FROM INDIVIDUAL DOGS 
Tables lOA-C list the initial transchest defibrillation values for 
the controls. Tables llA-C list the initial transchest defibrillation 
values for the amiodarone treated animals. Tables 12A-D list the 
follow-up transchest thresholds for the controls. Tables 13A-D list the 
follow-up transchest thresholds for the amiodarone treated animals. 
Tables 14A-E list the direct defibrillation thresholds and the chest 
measurements for the controls. Tables 15A-E list the direct 
defibrillation thresholds and chest measurements for the amiodarone 
treated animals. 
Table lOA. In! tial transchest defibrillation thresholds 
(controls) 
-------------------------------------------------------------
Leading Trailing Leading Trailing 
Dog Wt. Total Voltage Voltage Current Current 
Number M/F (Kg) Shocks (Volts) (Volts) (Amps) (Amps) 
-------------------------------------------------------------
5712 M 18 11 1180 520 19.00 8.50 
5733 M 12 6 780 340 10.20 4.40 
5762 F 13 7 680 280 7.80 3.20 
5774 M 20 10 800 360 10.40 4.40 
5771 F 22 3 880 380 12.60 5.40 
5772 M 15 5 800 340 9.40 4.20 
5802 F 17 6 640 280 11.20 4.80 
5780 F 20 12 680 300 11.20 4.80 
6031 F 19 8 820 360 12.40 5.60 
6041 F 16 10 760 320 12.80 5.60 
-------------------------------------------------------------
N = 10 10 10 10 10 10 
Average = 17 8 802 348 11.?0 5.09 
st. Dev. = 3 3 152 69 3.00 1.40 
% c. v. = 18 37 19 20 26 28 
-------------------------------------------------------------
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Table lOB. lni ti al transchest defibrillation 
thresholds (controls) 
------------------------------------------------------
Leading Trailing 
Dog Pulse Edge Edge Pulse 
Number Width Tilt Impedance Impedance Energy 
(msec) (%) (Ohms) (Ohms) (Joules) 
------------------------------------------------------
5712 3.70 55 62 61 41 
5733 4.50 57 76 77 17 
15762 5.00 59 87 88 12 
5774 4.40 58 77 82 17 
5771 4.00 57 70 70 21 
5772 4.50 55 85 81 17 
5802 3.40 57 57 58 12 
5780 3.80 57 61 63 14 
6031 3.80 55 66 64 19 
6041 3.70 56 59 57 18 
-----------------------------------------------------
N = 10 10 10 10 10 
Average = 4.08 57 70 70 19 
St. Dev. = .so 1 11 11 8 
% c. v. = 12 2 15 16 44 
-----------------------------------------------------
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Table lOC. Initial transchest defibrillation 
thresholds normalized on a body weight 
basis (controls) 
---------------------------------------------------
Peak Mean Peak Mean Pulse 
Dog Voltage Voltage Current Current Energy 
Number (V/Kg) (V/Kg) (Amp/Kg) (Amp/Kg) (J/Kg) 
---------------------------------------------------
5712 64.90 44.30 1.05 • 72 2.27 
5733 63.56 43.18 .83 • 56 1.41" 
5762 51.59 34.20 .59 .39 .94 
5774 40.00 27.55 .52 .35 .87 
5771 39.51 26.73 .57 .38 .96 
5772 51.76 34.79 .61 .42 1.09 
5802 38.05 25.89 .67 .45 .70 
5780 33.24 22.70 .55 .37 .68 
6031 44.00 29.98 .67 .46 1.04 
6041 47. 77 31.97 .80 .55 1.11 
---------------------------------------------------
N = 10 10 10 10 10 
Average = 47.44 32.13 .68 .46 1.11 
St. Dev. = 10.65 7.18 .16 .11 .46 
% c. v. = 22 22 24 25 42 
Table llA. Initial transchest defibrillation thresholds 
(amiodarone treated dogs) 
Leading Trailing Leading Trailing 
Dog Wt. Total Voltage Voltage Current Current 
number M/F (Kg) shocks (Volts) (Volts) (Amps) (Amps) 
-----------------------------------------------------------
5830 M 17 10 552 248 9.60 4.20 
5797 F 18 9 640 280 8.80 4.00 
5834 M 20 13 920 400 16.00 7.00 
5835 M 15 11 512 216 7.80 3.40 
5773 F 18 7 780 340 11.60 5.00 
5954 F 15 4 760 340 12.60 5.60 
5953 F 15 4 700 300 9. 20 4.20 
5878 F 17 4 760 340 9.60 4.40 
-----------------------------------------------------------
N = 8 8 8 8 8 8 
Average = 17 8 703 308 10.65 4.73 
St. Dev. = 2 3 132 59 2.65 1.13 
% c. v. = 12 38 19 19 25 24 
-----------------------------------------------------------
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Table llB. Initial transchest defibrillation 
thresholds ( amiodarone treated dogs) 
-----------------------------------------------------
Leading Trailing 
Dog Pulse Edge Edge Pulse 
Number width Tilt Impedance Impedance Energy 
(msec) (%) (Ohms) (Ohms) (Joules) 
-----------------------------------------------------
5830 3.40 56 58 59 9 
5797 4.10 55 73 70 12 
5834 3.60 56 58 57 26 
5835 3.90 56 66 64 8 
5773 3.90 57 67 68 17 
5954 3.60 56 60 61 17 
5953 4.40 54 76 71 14 
5878 4.40 54 79 77 16 
-----------------------------------------------------
N = 8 8 8 8 8 
Average = 3. 91 56 67 66 15 
St. Dev. = .37 1 8 7 6 
% c. v. = 10 2 12 11 39 
-----------------------------------------------------
Table uc·. Initial. transches t defibrilla ti on 
thresholds normalized on a body weight 
basis (amiodarone treated dogs) 
Peak Mean Peak Mean 
Dog Voltage Voltage Current Current Energy 
Number (V/Kg) (V/Kg) (Amp/Kg) (Amp/Kg) (J/Kg) 
---------------------------------------------------
5830 32.82 22.59 .57 .39 .52 
5797 36.10 24.57 .50 .34 .66 
5834 44.98 30.52 .78 .53 1.27 
5835 34.13 22.86 .52 .35- .51 
5773 44.00 29.89 .65 .44 .96 
5954 52.25 35.90 .87 .59 1.17 
5953 46.67 31.47 • 61 .43 .95 
5878 45.19 31.05 .57 .40 .97 
-------~------------------------------------------
N = 8 8 8 8 8 
Average = 42.02 28.61 .63 .43 .88 
st. Dev. = 6.87 4.75 .13 .09 .29 
% c. v. = 16 17 20 20 33 
---------------------------------------------------
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Table 12A. Follow-up transchest defibrillation thresholds 
(controls) 
------------------------------------------------------------
Leading Trailing Leading Trailing 
Dog Wt. Total Voltage Voltage Current Current 
Number M/F {Kg) Shocks (Volts) (Volts) (Amps) (Amps) 
------------------------------------------------------------
5712 M 20 18 1160 540 24.00 10.50 
5733 M 12 17 1060 480 17.50 8.00 
5762 F 14 4 660 280 8.80 3.80 
5774 M 19 6 840 380 10.40 4.60 
5771 F 22 7 840 360 11.80 5.00 
5772 M 15 9 920 400 15.40 6.80 
5802 F 17 8 660 280 10.40 4.40 
5780 F 22 14 1120 500 15.50 7.00 
6031 F 18 9 940 420 15.50 6.50 
6041 F 16 11 800 340 13.80 6.00 
------------------------------------------------------------
N = 10 10 10 10 10 10 
Average = 18 10 900 398 14.31 6.26 
St. Dev. = 3 5 175 89 4.42 2.00 
% c. v. = 19 45 19 22 31 32 
------------------------------------------------------------
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Table 12B. Follow-up transchest defibrillation 
thresholds (controls) 
---------------------------------------------------
Leading Trailing 
Dog Pulse Edge Edge Pulse 
Number Width Tilt Impedance Impedance Energy 
(msec) ( %) (Ohms) (Ohms) (Joule) 
---------------------------------------------------
5712 3.00 56 48 51 41 
5733 3.60 54 61 60 34 
5762 4.40 57 75 74 12 
5774 4.60 56 81 83 20 
5771 4.20 58 71 72 20 
5772 3.50 56 60 59 24 
5802 3.90 58 63 64 13 
5780 4.30 55 72 71 37 
6031 3.60 58 61 65 25 
6041 3.50 57 58 57 19 
---------------------------------------------------
N = 10 10 10 10 10 
Average = 3,86 56 65 65 24 
st. Dev. = .so l 10 9 10 
"% c. v. = 13 2 15 14 40 
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Table 12C. Follow-up body weight normalized 
transches t values (controls) 
--------------------------------------------------
Peak Mean Peak Mean Pulse 
Dog Voltage Voltage Current Current Energy 
Number (V/Kg) (V/Kg) {Amp/Kg) {Amp/Kg) (J/Kg) 
--------------------------------------------------
5712 58.00 40.54 1.20 .82 2.04 
5733 86.37 59.65 1.43 .99 2.75 
5762 48.40 32.50 .65 .44 .91 
5774 44.00 30.38 .54 .37 1.04 
5771 37. 71 25.43 .53 .36 .89 
5772 59.53 40.40 1.00 .68 1.58 
5802 38.21 25.66 .60 .40 .74 
5780 50.29 34.52 .70 .48 1.68 
6031 51.70 35.50 .85 .57 1.37 
6041 50.29 33.79 .87 .59 1.18 
--------------------------------------------------
N = 10 10 10 10 10 
Average = 52.45 35.84 .84 .57 1.42 
st. Dev. = 13.94 9.83 .30 .21 .62 
% c. v. = 27 27 36 36 44 
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Table 12D. Follow-up heart weight normalized transches t 
values (controls) 
--------------------------------------------------------------
Ventricle Peak Mean Peak Mean Pulse 
Dog Mass Voltage Voltage Current Current Energy 
Number (Grams) (V/g} (V/g} (A/lOOg} (A/lOOg} (J/lOOg} 
--------------------------------------------------------------
5712 108 10.71 7.49 22.16 15.08 37. 71 
5733 92 11. 56 7.98 19. 08 13. 24 36.80 
5762 90 7 .31 4.91 9.75 6.59 13. 71 
5774 154 5.44 3.76 6.74 4.61 12.84 
5771 160 5.25 3.54 7.38 4.95 12.43 
5772 130 7 .06 4.79 11.81 8.07 18.72 
5802 113 5.82 3.91 9.17 6.15 11.27 
5780 150 7.49 5.14 10.37 7.15 25.00 
6031 134 7.00 4. 81 11.54 7 .71 18.52 
6041 131 6.11 4.10 10.53 7.15 14.36 
--------------------------------------------------------------
N = 10 10 10 10 10 10 
Average = 126 7.37 5.04 11.85 8.07 20.14 
St. Dev. = 25 2.14 1,52 4.95 3.42 9.89 
% c. v. = 20 29 30 42 42 49 
Table 13A. Follow-up transchest defibrillation thresholds 
( amiodarone treated dogs} 
-----------------------------------------------------------
Leading Trailing Leading Trailing 
Dog Wt. Total Voltage Voltage Current Current 
Number M/F (Kg) Shocks (Volts) (Volts) (Amps) (Amps) 
-----------------------------------------------------------
5830 M 19 6 740 340 12.00 5.20 
5797 F 18 12 560 260 7.40 3.20 
5834 M 22 10 940 420 14.20 6.00 
5835 M 15 10 760 340 11.60 5.00 
5773 F 20 8 940 420 13.60 6.00 
5954 F 15 11 780 340 11.00 5.00 
5953 F 15 9 880 380 10.40 4.60 
5878 F 18 4 760 320 9.60 4.20 
-----------------------------------------------------------
N = 8 8 8 8 !! 8 
Average = 18 9 795 353 11.23 4.90 
st. Dev. = 3 3 125 53 2.18 .93 
% c. v. = 14 30 16 15 19 19 
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Table 13B. Follow-up transches t def ibrilla tion 
thresholds ( amiodarone treated dogs) 
-----------------------------------------------------
Leading Trailing 
Dog Pulse Edge Edge Pulse 
Number Width Tilt Impedance Impedance Energy 
(msec) (%) (Ohms) (Ohms) (Joule) 
-----------------------------------------------------
5830 3.70 57 62 65 16 
5797 4.50 57 76 81 9 
5834 3.90 58 66 70 25 
5835 3.80 57 66 68 16 
5773 4.10 56 69 70 26 
5954 4.00 55 71 68 17 
5953 4.80 56 85 83 22 
5878 4.60 56 79 76 16 
-----------------------------------------------------
N = 8 8 ·3 8 8 
Average = 4.18 56 72 73 18 
st. Dev. = • 41 1 8 6 5 
% c. v. = 10 2 11 9 30 
Table 13C. Follow-up body weight normalized 
transchest defibrillation values 
( amiodarone treated dogs) 
--------------------------------------------------
Peak Mean Peak Mean Pulse 
Dog Voltage Voltage Current Current Energy 
Number (V/Kg) (V/Kg) (Amp/Kg) (Amp/Kg) (J/Kg) 
--------------------------------------------------
5830 38.76 26.94 .63 .43 .84 
5797 31.59 22.06 .42 • 28 .51 
5834 43.08 29.58 .65 .44 l.i4 
5835 50.67 34.81 • 77 .52 1.08 
5773 48.09 33.02 .70 .48 1.32 
5954 50.47 34.29 .71 .49 1.12 
5953 60.50 40.93 • 72 .49 1.49 
5878 41.80 27.98 .53 .36 .90 
--------------------------------------------------
N = 8 8 8 8 8 
Average = 45.62 31.20 .64 .44 1.05 
St. Dev. = 8.79 5.80 .12 .08 .30 
% c. v. = 19 19 18 18 29 
--------------------------------------------------
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Table 13D. Follow-up heart weight normalized transches t 
defibrillation values (amiodarone treated dogs) 
--------------------------------------------------------------
Ventricle Peak Mean Peak Mean Pulse 
Dog Mass Voltage Voltage Current Current Energy 
Number (Grams) (V/g) (V/g) (A/lOOg) (A/lOOg) (J/lOOg) 
--------------------------------------------------------------
5830 112 6.62 4.60 10.73 7.27 14.27 
5797 133 4.22 2.94 5.57 3.77 6.81 
5834 138 6.81 4.68 10.29 6.90 17.99 
5835 112 6.82 4.68 10.40 7.03 14.53 
5773 130 7.24 4.97 10.48 7.16 19.87 
5954 124 6.30 4. 28 8.89 6.15 13.95 
5953 111 7.91 5.35 9.35 6.39 19.48 
5878 133 5.73 3.84 7.24 4.93 12.38 
--------------------------------------------------------------
N; 8 8 8 8 8 8 
Average ; 124 6.46 4.42 9.12 6.20 14.91 
st. Dev. ; 11 1.11 .74 1.84 1.24 4.28 
% c. v. ; 9 17 17 20 20 29 
-------------------------------------~------------------------
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Table 14A. Direct defibrillation thresholds 
(controls) 
Leading Trailing Leading Trailing 
Dog Wt, Total Voltage Voltage Current Current 
Number M/F (Kg) Shocks (Vol ts) (Volts) (Amps) (Amps) 
------------------------------------------------------------
5733 M 12 10 376 160 4.40 1.90 
5762 F 14 8 272 112 3.00 1. 20 
5774 M 19 17 392 160 5.10 2.20 
5771 F 22 5 352 144 4.80 2.00 
5802 F 17 14 256 104 3.40 1.40 
5780 F 22 4 352 144 5.20 2,20 
5782 M 19 12 328 136 4.40 1.80 
6041 F 18 7 320 128 4.20 1. 70 
N = 8 8 8 8 8 8 
Average = 18 10 331 136 4.31 1.80 
St. Dev. = 3 4 48 21 .78 .36 
% c. v. = 19 44 14 15 18 20 
------------------------------------------------------------
Table 14B. Direct defibrillation thresholds 
(controls) 
----------------------------~----------------------
Leading Trailing 
Dog Pulse Edge Edge Pulse 
Number Width Tilt Impedance Impedance Energy 
(msec) (%) (Ohms) (Ohms) (Joules) 
---------------------------------------------------
5733 5.00 57 85 84 3.96 
5762 5.30 60 91 93 2.10 
5774 4.60 57 77 73 4.37 
5771 4.50 58 73 72 3.52 
5802 4.60 59 75 74 1.87 
5780 4.20 58 68 65 3.52 
5782 4.50 59 75 76 3.04 
6041 4.80 60 76 75 3.06 
---------------------------------------------------
N = 8 8 8 8 8 
Average = 4.69 58 78 77 3.18 
st. Dev. = .34 1 7 9 0.86 
% c. v. = 7 2 9 11 29 
---------------------------------------------------
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Table 14C. Direct defibrillation, body weight 
normalized values (controls) 
Peak Mean Peak Mean Pulse 
Dog Voltage Voltage ·Current Current Energy 
Number (V/Kg) (V/Kg) (Amp/Kg) (Amp/Kg) (J/Kg) 
--------------------------------------------------
5733 30.64 20.60 .36 .24 .33 
5762 19.95 13.22 .22 .14 .15 
5774 20.53 13.56 .27 .18 • 23 
5771 15.80 10.45 .22 .14 .16 
5802 14.82 9.77 .20 .13 .11 
5780 15.80 10.45 .23 .16 .16 
5782 17.60 11. 70 .24 .16 .16 
6041 18.05 11.82 .24 .16 .17 
--------------------------------------------------
N = 
Average = 
st. Dev. = 
% c. v. = 
8 
19.15 
5.06 
26 
8 
12.70 
3.46 
27 
8 
.25 
.05 
20 
8 
.16 
.03 
21 
8 
.18 
.07 
37 
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Table 14D. Direct defibrillation thresholds, heart weight 
normalized values (controls) 
--------------------------------------------------------------
Ventricle Peak Mean Peak Mean Pulse 
Dog Mass Voltage Yol tage Current Current Energy 
Number (Grams) (V/gr.) (V/gr.) (A/lOOg) (A/lOOg) (J/lOOg) 
--------------------------------------------------------------
5712a 108 
5733 92 4.10 2.76 4.80 3.25 4.37 
5762 90 3.01 2.00 3.32 2.18 2.20 
5774 154 2.54 1.68 3.31 2.24 2.88 
5771 160 2.20 1.45 3.00 2.00 2.24 
5772a 130 
5802 113 2.26 1.49 3.00 1.99 1.65 
5780 150 2.35 1.56 3.48 2.33 2.45 
603la 134 
6041 131 2.44 1.60 3.21 2.11 2.28 
--------------------------------------------------------------
N = 10 7 7 7 7 
Average = 127 2.70 1. 79 3.44 2.30 
St. Dev. = 25 .67 .46 .62 .44 
% c. v. = 20 25 26 18 19 
a 
Died during open chest surgery, no direct threshold. 
Table 14E. Chest parameters 
(controls) 
Chest Chest Wall 
Dog Breadth Thickness 
Number (cm) (cm) 
5762 
5774 
5771 
5802 
5780 
6031 
6041 
N = 
11.50 
10.60 
11.60 
9.50 
13.40 
11.60 
12.10 
7 
1.00 
1.60 
1.50 
.90 
1.40 
1.20 
1.30 
7 
Average = 11.47 1.27 
st. Dev. = 1.21 .26 
% c. v. = 11 20 
----------------------------
7 
2.58 
.87 
34 
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Table 15A. Direct defibrillation thresholds 
(amiodarone treated dogs) 
------------------------------------------------------------
Leading Trailing Leading Trailing 
Dpg Wt. Total Voltage Voltage Current Current 
Number M/F (Kg) Shocks (Volts) (Volts) (Amps) (Amps) 
------------------------------------------------------------
5830 M 19 7 360 152 4.40 1.80 
5797 F 18 13 212 84 3.00 1.20 
5834 M 22 6 360 152 4.20 1. 70 
5835 M 15 8 232 96 2.80 1.20 
5773 F 20 9 360 152 4.50 1.80 
5954 F 15 3 360 160 4.20 1.80 
5953 F 15 7 232 96 2.90 1.20 
5878 F 18 9 224 96 3.30 1.40 
------------------------------------------------------------
N = 8 8 8 8 8 8 
Average = 18 8 293 124 3.66 1.51 
st. Dev. = 3 3 72 33 .73 • 29 
% c. v. = 14 37 25 27 20 19 
------------------------------------------------------------
Table 15B. Direct defibrillation thresholds 
( amiodarone treated . .dogs) 
---------------------------------------------------
Leading Trailing 
Dog Pulse Edge Edge Pulse 
Number Width Tilt Impedance Impedance Energy 
(msec) (%) (Ohms) (Ohms) (Joules) 
---------------------------------------------------
5830 4.90 59 82 84 3.61 
5797 4.70 60 71 70 1.44 
5834 5.20 60 86 89 3.74 
5835 5.00 57 83 80 1.50 
5773 4.80 60 80 84 3.60 
5954 4.70 57 86 89 3.30 
5953 4.80 59 80 80 1.50 
5878 4.30 58 68 69 1.44 
---------------------------------------------------
N = 
Average = 
st. Dev. = 
% c. v. = 
8 8 
4.80 59 
.26 1 
5 2 
8 
79 
7 
8 
8 
81 
8 
10 
8 
2.52 
1.13 
44 
93 
Table 15C. Direct defibrillation values, 
norm~lized by body weight 
( amiodarone treated dogs) 
----~---------------------------------------------
Peak Mean Peak Mean Pulse 
Dog Voltage Voltage Current Current Energy 
Number (V/Kg) (V/Kg) (Amp/Kg) (Amp/Kg) (J/Kg) 
--------------------------------------------------
5830 18.86 12.64 • 23 .15 .19 
5797 11.96 7.80 .17 .11 .08 
5834 16.50 11.06 .19 .13 .17 
5835 15.47 10.28 .19 .13 .10 
5773 18.42 12.34 .23 .15 .18 
5954 23.29 15. 96 .27 .18 .22 
5953 15.95 10.60 .20 .13 .10 
5878 12.32 8.31 .18 .12 .08 
--------------------------------------------------
N = 8 8 8 8 8 
Average = 16.60 11.12 .21 .14 .14 
St. Dev. = 3.68 2.59 .03 .02 .06 
% c. v. = 22 23 16 17 39 
-------------------------------------------~------
Table 15D. Direct defibrillation, heart weight normalized 
values ( ami od arone treated dogs) 
--------------------------------------------------------------
Ventricle Peak Mean Peak Mean Pulse 
Dog Mass Voltage Voltage Current Current Energy 
Number (Grams) (V/gr.) (V/gr.) (A/lOOg) (A/lOOg) (J/lOOg) 
--------------------------------------------------------------
5830 
5797 
5834 
5835 
5773 
5954 
5953 
5878 
N = 
Average = 
st. Dev. = 
% c. v. = 
112 
133 
138 
112 
130 
124 
111 
133 
8 
124 
11 
9 
3.22 
1.60 
2.61 
2.08 
2. 77 
2. 91 
2.09 
1.69 
8 
2.37 
.59 
25 
2.16 
1.04 
1.75 
1.38 
1.86 
1.99 
1.39 
1.14 
8 
1.59 
.41 
26 
3.94 
2.26 
3.04 
2.51 
3.47 
3.39 
2.61 
2.49 
8 
2.96 
.59 
20 
2.60 
1;48 
2.00 
1.69 
2.27 
2.29 
l. 73 
1.67 
8. 
1.97 
.39 
20 
3. 23 
1.03 
2.63 
1.40 
2.75 
2. 77 
1.36 
1.15 
8 
2.04 
.88 
43 
94 
Table 15E. Chest parameters 
(amiodarone treated dogs) 
-------------------------------------
Chest Chest Wall 
Dog Breadth Thickness 
Number (cm) (cm) 
5830 11.00 1.20 
5797 8.90 _a 
5834 12.10 1.90 
5835 9.40 1.60 
5773 11.00 _a 
5954 9.10 1.30 
5953 9.70 1.10 
5878 11.40 1.80 
N = 8 6 
Average = 10.33 1.48 
St. Dev. = 1.19 .33 
% c. v. = 12 22 
a 
No measurement taken. 
Method file name: 
Default Sample Name: 
Operator: 
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APPENDIX D: METHOD USED FOR HPLC 
B:M9DLY 
Heart Tissue 
JEG Date: 02-07-1986 
ACQUISITION PARAMETERS 
-----------------------------------------------------------------------
SINGLE OR DUAL CHANNEL (1 OR 2) 
RUN TIME (minutes) 
END TIME FOR PLOTS (default=RUN TIME) 
SOLVENT DELAY TIME (minutes) 
PEAK DETECTION THRESHOLD (microv/sec) 
MINIMUM PEAK WIDTH (seconds) 
TIME FOR ONE SAMPLE (seconds) 
NUMBER OF REAL TIME CRT PAGES TO PLOT (0 TO 99) 
REAL TIME PLOT FULL SCALE FOR CH.O (millivolts) 
REAL TIME FULL SCALE FOR CH.l (millivolts) 
HARD COPY REAL TIME PLOT 
AUTO ZERO REAL TIME PLOT 
1.00 
9.00 
9.00 
o.oo 
o.os 
10.00 
1.00 
1.00 
100.00 
200.00 
NO 
NO 
-----------------------------------------------------------------------
RECORD AREA TABLES ON DISK YES 
RECORD RAW DATA YES 
NUMBER OF CRT PAGES FOR REPLOT (1 TO 99) 1.00 
VERTICAL SCALE FACTOR FOR REPLOT (units of largest peak) 1.00 
OFFSET FOR THE REPLOT (millivolts) 0.00 
PUT NAMES ON REPLOT? NO 
PRINT AREA PERCENT REPORT YES 
PRINT EXTERNAL STANDARD REPORT NO 
PRINT INTERNAL STANDARD REPORT NO 
FINAL REPORT AREA REJECT (microvolt-sec) 0.00 
LINK TO USER PROGRAM NO 
FORCE DROP LINE INTEGRATION YES 
FORCE COMMON BASE LINE YES 
FULL SCALE RANGE FOR A.D.C. (3=1VOLT, 1=2VOLT, O=lOVOLT) 3.00 
AREA REJECT FOR REFERENCE PEAKS? 
% RET TIME WINDOW FOR REFERENCE PEAKS 
RET TIME WINDOW IN SECONDS FOR REF.PEAKS 
AREA OR PEAK HEIGHT QUANTITATION (0 OR 1) 
PRINT GROUP REPORT 
NUMBER OF CALIBRATION LEVELS (1 TO 6) 
1000.00 
0.00 
o.oo 
o.oo 
NO 
4.00 
96 
FIT TYPE FOR MULTILEVEL CALIBRATION (O=PT-TO-PT, l=LINEAR) 
LIST COMPONENTS NOT FOUND IN SAMPLE? 
INCLUDE UNKNOWN PEAKS IN REPORTS? 
UPDATE RESPONSE FACTORS WITH REPLACEMENT (0) OR AVERAGE (1) 
DEFAULT DILUTION FACTRO 
DEFAULT SAMPLE AMOUNT 
DEFAULT AMOUNT OF INTERNAL STANDARD 
PRINT GPC MW DISTRIBUTION 
PRINT SIMULATED DISTILLATION REPORT 
1.00 
YES 
YES 
0.00 
1.00 
20.00 
1.00 
o.oo 
o.oo 
